JP2016540000A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016540000A5 JP2016540000A5 JP2016538587A JP2016538587A JP2016540000A5 JP 2016540000 A5 JP2016540000 A5 JP 2016540000A5 JP 2016538587 A JP2016538587 A JP 2016538587A JP 2016538587 A JP2016538587 A JP 2016538587A JP 2016540000 A5 JP2016540000 A5 JP 2016540000A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- use according
- dioxolo
- piperazin
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 3- {4- [4- (8-oxo-8H- [1,3] dioxolo [4,5-g] chromen-7-yl) -butyl] -piperazin-1-yl} -phenyl Chemical group 0.000 claims 5
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 201000007185 autism spectrum disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000003840 hydrochlorides Chemical class 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000003997 social interaction Effects 0.000 claims 2
- KPYSYYIEGFHWSV-QMMMGPOBSA-N (3R)-4-amino-3-(4-chlorophenyl)butanoic acid Chemical compound OC(=O)C[C@@H](CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-QMMMGPOBSA-N 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N Amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 Amantadine Drugs 0.000 claims 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims 1
- 229960000794 Baclofen Drugs 0.000 claims 1
- NWPJLRSCSQHPJV-UHFFFAOYSA-N Carpipramine Chemical compound C1CN(CCCN2C3=CC=CC=C3CCC3=CC=CC=C32)CCC1(C(=O)N)N1CCCCC1 NWPJLRSCSQHPJV-UHFFFAOYSA-N 0.000 claims 1
- 229960000700 Carpipramine Drugs 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N Memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 101710008205 OXT Proteins 0.000 claims 1
- 102100017240 OXT Human genes 0.000 claims 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N Oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims 1
- 229960001723 Oxytocin Drugs 0.000 claims 1
- ZPPHFUACQVCJTO-UHFFFAOYSA-N [1,3]dioxolo[4,5-g]chromen-8-one Chemical compound C1=C2C(=O)C=COC2=CC2=C1OCO2 ZPPHFUACQVCJTO-UHFFFAOYSA-N 0.000 claims 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims 1
- 229960004047 acamprosate Drugs 0.000 claims 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- 101700057139 oxyT Proteins 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 229960003726 vasopressin Drugs 0.000 claims 1
Claims (7)
- 自閉症スペクトラム障害の治療を目的とする薬剤の製造のための、Ｎ−（３−｛４−［４−（８−オキソ−８Ｈ−［１，３］ジオキソロ［４，５−ｇ］クロメン−７−イル）−ブチル］−ピペラジン−１−イル｝−フェニル）−メタンスルフォンアミドまたはその薬学的に許容可能な塩の使用。
- Ｎ−（３−｛４−［４−（８−オキソ−８Ｈ−［１，３］ジオキソロ［４，５−ｇ］クロメン−７−イル）−ブチル］−ピペラジン−１−イル｝−フェニル）−メタンスルフォンアミドの薬学的に許容可能な塩が塩酸塩である、請求項１に記載の使用。
- 前記薬剤が社会的相互作用の欠陥の治療を目的とするものである、請求項１または２に記載の使用。
- Ｎ−（３−｛４−［４−（８−オキソ−８Ｈ−［１，３］ジオキソロ［４，５−ｇ］クロメン−７−イル）−ブチル］−ピペラジン−１−イル｝−フェニル）−メタンスルフォンアミドまたはその薬学的に許容可能な塩と薬学的に許容可能な賦形剤とを含んでなる、自閉症スペクトラム障害の治療のための医薬組成物。
- Ｎ−（３−｛４−［４−（８−オキソ−８Ｈ−［１，３］ジオキソロ［４，５−ｇ］クロメン−７−イル）−ブチル］−ピペラジン−１−イル｝−フェニル）−メタンスルフォンアミドの薬学的に許容可能な塩が塩酸塩である、請求項４に記載の使用のための医薬組成物。
- 社会的相互作用の欠陥の治療のための、請求項４または５に記載の使用のための医薬組成物。
- メマンチン、アマンタジン、バクロフェン、Ｒ−バクロフェン、フェノバム（phenobam）、アカンプロセート、ブメタミド（bumetamide）、カルピプラミン、オキシトシン、バソプレシンおよびこれらの混合物、からなる群から選択される化合物と組合せられた、請求項４〜６のいずれか一項に記載の使用のための医薬組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306726.4 | 2013-12-13 | ||
| EP13306726 | 2013-12-13 | ||
| PCT/EP2014/077635 WO2015086836A1 (en) | 2013-12-13 | 2014-12-12 | A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016540000A JP2016540000A (ja) | 2016-12-22 |
| JP2016540000A5 true JP2016540000A5 (ja) | 2018-02-01 |
| JP6419826B2 JP6419826B2 (ja) | 2018-11-07 |
Family
ID=49883003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538587A Expired - Fee Related JP6419826B2 (ja) | 2013-12-13 | 2014-12-12 | 自閉症スペクトラム障害の治療のためのドーパミンｄ３受容体拮抗薬としてのクロモン誘導体 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US10028948B2 (ja) |
| EP (1) | EP3079688B1 (ja) |
| JP (1) | JP6419826B2 (ja) |
| KR (1) | KR102280530B1 (ja) |
| CN (1) | CN105792824B (ja) |
| AU (1) | AU2014363428B2 (ja) |
| BR (1) | BR112016012552A8 (ja) |
| CA (1) | CA2932791C (ja) |
| CY (1) | CY1119907T1 (ja) |
| DK (1) | DK3079688T3 (ja) |
| ES (1) | ES2657706T3 (ja) |
| HK (1) | HK1223563A1 (ja) |
| HR (1) | HRP20180323T8 (ja) |
| HU (1) | HUE036035T2 (ja) |
| IL (1) | IL245996B (ja) |
| LT (1) | LT3079688T (ja) |
| MA (1) | MA39076A1 (ja) |
| MX (1) | MX2016007612A (ja) |
| MY (1) | MY172937A (ja) |
| NO (1) | NO3079688T3 (ja) |
| NZ (1) | NZ720868A (ja) |
| PL (1) | PL3079688T3 (ja) |
| PT (1) | PT3079688T (ja) |
| RS (1) | RS56931B1 (ja) |
| RU (2) | RU2686110C1 (ja) |
| SA (1) | SA516371298B1 (ja) |
| SI (1) | SI3079688T1 (ja) |
| TN (1) | TN2016000213A1 (ja) |
| UA (1) | UA117271C2 (ja) |
| WO (1) | WO2015086836A1 (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG192507A1 (en) | 2008-07-16 | 2013-08-30 | Richter Gedeon Nyrt | Pharmaceutical formulations containing dopamine receptor ligands |
| US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
| HU231500B1 (hu) | 2019-04-10 | 2024-04-28 | Richter Gedeon Nyrt | Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére |
| US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
| KR20220021157A (ko) | 2020-08-13 | 2022-02-22 | 원광대학교산학협력단 | 옥시토신 호르몬 증가효과를 갖는 자폐스펙트럼장애 아동 개선용 교육시스템 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2682953B1 (fr) | 1991-10-23 | 1995-04-21 | Inst Nat Sante Rech Med | Nouveaux derives de naphtamides, leur procede de preparation et leur application dans le domaine therapeutique. |
| DE4229880A1 (de) * | 1992-09-04 | 1994-03-31 | Knauf Siegfried | Medikament bzw. Medikamentenzusammensetzung |
| EA200100428A1 (ru) * | 1998-10-08 | 2001-10-22 | Смитклайн Бичам Плс | Производные тетрагидробензазепина, полезные в качестве модуляторов допаминовых d3 рецепторов (антипсихотические агенты) |
| EP1793671B1 (en) * | 2004-09-20 | 2011-04-27 | Mount Sinai School of Medicine | Use of memantine (namenda) to treat autism, compulsivity, and impulsivity |
| EP2263665A1 (en) * | 2009-06-02 | 2010-12-22 | Pharnext | New compositions for treating CMT and related disorders |
| FR2949465B1 (fr) | 2009-09-01 | 2011-08-12 | Pf Medicament | Derives chromones, leur procede de preparation et leurs applications therapeutiques |
| US20110294879A1 (en) * | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
| WO2012157463A1 (en) * | 2011-05-13 | 2012-11-22 | Semiconductor Energy Laboratory Co., Ltd. | Semiconductor device |
| FR2976179A1 (fr) * | 2011-06-09 | 2012-12-14 | Pf Medicament | Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent |
-
2014
- 2014-12-12 HU HUE14812465A patent/HUE036035T2/hu unknown
- 2014-12-12 LT LTEP14812465.4T patent/LT3079688T/lt unknown
- 2014-12-12 JP JP2016538587A patent/JP6419826B2/ja not_active Expired - Fee Related
- 2014-12-12 RU RU2016125829A patent/RU2686110C1/ru active
- 2014-12-12 UA UAA201607311A patent/UA117271C2/uk unknown
- 2014-12-12 NO NO14812465A patent/NO3079688T3/no unknown
- 2014-12-12 KR KR1020167015313A patent/KR102280530B1/ko active IP Right Grant
- 2014-12-12 NZ NZ720868A patent/NZ720868A/en not_active IP Right Cessation
- 2014-12-12 CN CN201480066587.4A patent/CN105792824B/zh not_active Expired - Fee Related
- 2014-12-12 RS RS20180196A patent/RS56931B1/sr unknown
- 2014-12-12 WO PCT/EP2014/077635 patent/WO2015086836A1/en active Application Filing
- 2014-12-12 CA CA2932791A patent/CA2932791C/en active Active
- 2014-12-12 US US15/103,470 patent/US10028948B2/en active Active
- 2014-12-12 SI SI201430603T patent/SI3079688T1/en unknown
- 2014-12-12 ES ES14812465.4T patent/ES2657706T3/es active Active
- 2014-12-12 MY MYPI2016702136A patent/MY172937A/en unknown
- 2014-12-12 MA MA39076A patent/MA39076A1/fr unknown
- 2014-12-12 TN TN2016000213A patent/TN2016000213A1/en unknown
- 2014-12-12 EP EP14812465.4A patent/EP3079688B1/en active Active
- 2014-12-12 PL PL14812465T patent/PL3079688T3/pl unknown
- 2014-12-12 DK DK14812465.4T patent/DK3079688T3/da active
- 2014-12-12 AU AU2014363428A patent/AU2014363428B2/en not_active Ceased
- 2014-12-12 RU RU2019104946A patent/RU2019104946A/ru unknown
- 2014-12-12 PT PT148124654T patent/PT3079688T/pt unknown
- 2014-12-12 MX MX2016007612A patent/MX2016007612A/es active IP Right Grant
- 2014-12-12 BR BR112016012552A patent/BR112016012552A8/pt not_active Application Discontinuation
-
2016
- 2016-06-02 IL IL245996A patent/IL245996B/en active IP Right Grant
- 2016-06-12 SA SA516371298A patent/SA516371298B1/ar unknown
- 2016-10-17 HK HK16111955.2A patent/HK1223563A1/zh not_active IP Right Cessation
-
2018
- 2018-02-09 CY CY20181100159T patent/CY1119907T1/el unknown
- 2018-02-22 HR HRP20180323TT patent/HRP20180323T8/hr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120049T1 (el) | (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i | |
| JP2016540000A5 (ja) | ||
| ES2601127T3 (es) | Derivado de pirazol y su uso con fines médicos | |
| HRP20180323T1 (hr) | Derivat kromona kao antagonist dopaminskog receptora d3 za njegovu upotrebu u liječenju spektra autističnih poremećaja | |
| JP2015534562A5 (ja) | ||
| JP2015083580A5 (ja) | ||
| JP2013520405A5 (ja) | ||
| JP2016518337A5 (ja) | ||
| JP2013542247A5 (ja) | ||
| JP2015525757A5 (ja) | ||
| BR112015018168A2 (pt) | inibidores de rock suaves | |
| CL2012001836A1 (es) | Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros. | |
| WO2016109217A3 (en) | Btk inhibitors | |
| EA201691789A1 (ru) | Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты | |
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| PH12015502406A1 (en) | Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof | |
| EA201890532A1 (ru) | Новые аннелированные бензамиды | |
| JP2013533867A5 (ja) | ||
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| JP2017515840A5 (ja) | ||
| CO6592109A2 (es) | Nueva forma cristalina de un derivado de ciclopropilbenzamida | |
| WO2015173701A3 (en) | Pharmaceutical compositions comprising danirixin for treating infectious diseases | |
| EA201591415A1 (ru) | Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии | |
| ECSP15033649A (es) | Un medicamento combinado que comprende fenilefrina y paracetamol | |
| JP2016540799A5 (ja) |